Lead Product(s): VTA-100
Therapeutic Area: Genetic Disease Product Name: VTA-100
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Cambrian Biopharma
Deal Size: $32.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 23, 2021
Vita’s lead therapy, VTA-100, is currently undergoing investigational new drug (IND)-enabling studies for the treatment of limb-girdle muscular dystrophy (LGMD) 2A/R1.